公开(公告)号：US12098203B2

公开(公告)日：2024-09-24

申请号：US16608555

申请日：2018-06-04

申请人： Numab Therapeutics AG

发明人： David Urech ,  Tea Gunde ,  Sebastian Meyer ,  Christian Hess ,  Alexandre Simonin

IPC分类号： C07K16/44 ,  C07K16/28 ,  C07K16/32

CPC分类号： C07K16/2809 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

摘要： This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.

公开(公告)号：US12037400B2

公开(公告)日：2024-07-16

申请号：US17151695

申请日：2021-01-19

申请人： TSINGHUA UNIVERSITY

发明人： Bai Lu ,  Wei Guo ,  Hongyang Yao

IPC分类号： A61K39/395 ,  A61K38/00 ,  A61K38/18 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  A61P9/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/28 ,  A61P27/00 ,  A61P27/02 ,  A61P27/06 ,  C07K14/00 ,  C07K14/48 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C12P21/08 ,  G01N33/53 ,  A61K9/00 ,  A61K38/17 ,  A61L27/38 ,  A61P21/00 ,  A61P25/14 ,  A61P25/16 ,  C07K14/47 ,  C07K14/705 ,  C12N5/0793

CPC分类号： C07K16/2863 ,  A61K38/185 ,  A61P9/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/28 ,  A61P27/00 ,  A61P27/02 ,  A61P27/06 ,  C07K14/48 ,  C07K16/00 ,  C07K16/2878 ,  A61K9/0048 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/18 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/507 ,  A61L27/383 ,  A61L2300/414 ,  A61P21/00 ,  A61P25/14 ,  A61P25/16 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70578 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/35 ,  C07K2317/50 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/62 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/31 ,  C12N5/0619 ,  C12Y207/10001 ,  G01N2333/46 ,  G01N2333/70575 ,  G01N2500/10

摘要： Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

公开(公告)号：US12012449B2

公开(公告)日：2024-06-18

申请号：US17525421

申请日：2021-11-12

申请人： AMGEN INC.

发明人： Jennifer E. Towne ,  Janet D. Cheng ,  Jason C. O'Neill ,  Yu Zhang ,  Yu Sun ,  Heather Cerne ,  Derek E. Piper ,  Randal R. Ketchem

IPC分类号： A61K39/395 ,  A61K47/68 ,  C07K16/24 ,  A61K39/00

CPC分类号： C07K16/244 ,  A61K39/395 ,  A61K47/6845 ,  C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92

摘要： Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

公开(公告)号：US11976112B2

公开(公告)日：2024-05-07

申请号：US17713087

申请日：2022-04-04

申请人： GENZYME CORPORATION

发明人： Huawei Qiu ,  Clark Pan ,  Julie Bird

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/22 ,  C07K16/46 ,  C12N15/11 ,  C12N15/62 ,  A61K39/00

CPC分类号： C07K16/22 ,  A61K39/395 ,  A61K39/3955 ,  C07K16/00 ,  C07K16/46 ,  C12N15/11 ,  C12N15/62 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/23 ,  C07K2319/73

摘要： An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

公开(公告)号：US20240117036A1

公开(公告)日：2024-04-11

申请号：US18320599

申请日：2023-05-19

申请人： MacroGenics, Inc.

发明人： Ezio BONVINI ,  Paul A. MOORE ,  Jonathan C. LI ,  Leslie S. JOHNSON ,  Kalpana SHAH

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2815 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2878 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.

公开(公告)号：US11845792B2

公开(公告)日：2023-12-19

申请号：US17077514

申请日：2020-10-22

申请人： University of Southern California

发明人： Parkash Gill ,  Ren Liu ,  Amy Lee

IPC分类号： C07K16/28 ,  C07K16/18 ,  C07K16/30 ,  A61K49/00 ,  A61K47/68 ,  A61K39/00 ,  G01N33/574

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6898 ,  A61K49/0032 ,  A61K49/0058 ,  C07K16/18 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2333/705

摘要： This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface GRP78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-GRP78 antibodies, or antigen-binding fragments thereof, have a high affinity for GRP78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit GRP78. Importantly, these isolated novel antibodies and antigen-binding fragments thereof, attenuate PI3K signaling and promote apoptosis in tumor cells, while leaving normal cells unaffected. The antibodies and antigen-binding fragments are useful for UPR-targeted cancer therapeutic treatments.

公开(公告)号：US20230365707A1

公开(公告)日：2023-11-16

申请号：US18134844

申请日：2023-04-14

申请人： BioNTech Research and Development, Inc.

发明人： Ritsuko Sawada ,  Shu-Man Sun ,  Wolfgang Scholz

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K51/10 ,  C07K16/30 ,  A61K39/00 ,  A61K31/337 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/2896 ,  C07K16/28 ,  A61K39/39533 ,  A61K45/06 ,  A61K51/1045 ,  A61K51/1057 ,  C07K16/3076 ,  A61K39/0011 ,  A61K31/337 ,  A61K39/39558 ,  A61K51/1027 ,  A61K51/1093 ,  G01N33/57438 ,  G01N33/577 ,  C07K2317/56 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  A61K2039/6081 ,  C07K2317/626

摘要： The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

公开(公告)号：US20230348598A1

公开(公告)日：2023-11-02

申请号：US18331556

申请日：2023-06-08

申请人： Immatics Biotechnologies GmbH

发明人： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

IPC分类号： C07K16/28 ,  C07K16/10 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/2809 ,  C07K16/1045 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/626 ,  C07K2317/94

摘要： The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

公开(公告)号：US11793888B2

公开(公告)日：2023-10-24

申请号：US16834481

申请日：2020-03-30

申请人： Sangamo Therapeutics, Inc.

发明人： Michael C. Holmes ,  Brigit E. Riley

IPC分类号： A61K35/12 ,  A61K48/00 ,  C07K16/32 ,  A61K35/28 ,  A61P35/00 ,  A61P25/16 ,  C12N15/86 ,  C07K16/18 ,  C07K16/30 ,  C12N15/62 ,  A61K39/00

CPC分类号： A61K48/0058 ,  A61K35/12 ,  A61K35/28 ,  A61P25/16 ,  A61P35/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/32 ,  C12N15/62 ,  C12N15/86 ,  A01K2227/105 ,  A01K2267/03 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2319/31 ,  C12N2750/14143

摘要： Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.

公开(公告)号：US20230272059A1

公开(公告)日：2023-08-31

申请号：US17890857

申请日：2022-08-18

申请人： Tillotts Pharma AG

发明人： Tea GUNDE ,  Sebastian Meyer ,  Esther Maria Furrer

IPC分类号： C07K16/24

CPC分类号： C07K16/241 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/622 ,  C07K2317/626

摘要： The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.